TABLE 3.

Effect of antibody reactivitya on JEV double-amino acid mutant VLPs

MutationsVirus titera
PolyclonebGroupSubgroupComplexSubcomplexType
MHIAF (JEV)c6B6C-1 (SLEV)4G2 (DENV-2)23-1 (WNV)23-2 (JEV)5-2 (JEV)2B5B-3 (SLEV)6B4A-10 (JEV)16 (JEV)1B5D-1 (SLEV)J3 14 H5-2 (JEV)
None5.96.3≥6.8≥6.8≥6.84.96.35.45.95.93.0
G106K/L107D5.4 3.0 <3.0<3.0 3.9 <3.0<3.05.45.9<3.03.0
G106K/L107R5.4 5.9 <3.0<3.0 4.9 <3.0<3.05.45.9<3.03.0
G106K/L107F 4.9 <3.0<3.0 4.9 ≥6.8<3.0<3.05.45.9<3.0<3.0
G106V/L107D5.4<3.0<3.0 3.0 5.9<3.0<3.05.45.9 3.5 3.0
G106V/L107R5.4<3.0<3.0<3.0 4.4 <3.0<3.04.95.9 3.5 3.0
G106V/L107F 4.9 3.9 <3.0 5.9 4.9 <3.0<3.05.45.4<3.03.0
G106D/L107D5.4<3.0<3.0 3.0 3.0 <3.0<3.04.95.9<3.03.5
G106D/L107R 4.9 3.0 <3.0<3.06.3<3.0<3.04.95.9<3.03.0
G106D/L107F5.45.9≥6.8 5.4 ≥6.8<3.06.35.45.94.93.0
  • a Ag-ELISA was used to determine the reciprocal end point titers (log10) for secreted VLP antigens. The numbers shown in boldface are the end point titers decreased below that of the WT by at least two threefold dilutions.

  • b Group, recognized by all flaviviruses examined; subgroup, recognized by more than one serocomplex; complex, recognized by all members of JEV complex; subcomplex, not recognized by all members of the serocomplex; type, recognized by JEV only.

  • c Virus against which antibody was raised.